Myomo (MYO) Cash from Financing Activities (2016 - 2025)
Myomo (MYO) reported Cash from Financing Activities of -$50000.0 for Q3 2025, up 74.94% on a YoY basis from -$28581.7 in Q3 2024, and down 101.25% quarter-over-quarter from $4.0 million in Q2 2025.
Myomo (MYO) Cash from Financing Activities (2016 - 2025) Analysis & Trends
Myomo has reported Cash from Financing Activities for 10 years, with the latest figure at -$50000.0 in Q3 2025.
- For the quarter ending Q3 2025, Cash from Financing Activities rose 74.94% year-over-year to -$50000.0; the trailing twelve-month figure through Sep 2025 stood at $19.7 million (up 281.28% YoY), and the FY2024 full-year result was $20.9 million, up 115.5% from the prior year.
- Cash from Financing Activities for Q3 2025 stood at -$50000.0, down from $4.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $15.8 million in Q4 2024, with the low at -$199500.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $3.2 million across 5 years, with a median of $1.1 million in 2021.
- The largest YoY upside for Cash from Financing Activities was 50870932.26% in 2024 against a maximum downside of 105.05% in 2024.
- Myomo's Cash from Financing Activities stood at $4.8 million in 2021, then plunged by 92.12% to $376858.0 in 2022, then plunged by 99.99% to $31.0 in 2023, then soared by 50870932.26% to $15.8 million in 2024, then plunged by 100.32% to -$50000.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$50000.0 (Q3 2025), $4.0 million (Q2 2025), and -$36506.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Myomo | 49.44 Mn | 31.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -50,000.00 |
| Sep 30, 2025 | -50,000.00 |
| Jun 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 4.00 Mn |
| Mar 31, 2025 | -36,506.00 |
| Mar 31, 2025 | -36,506.00 |
| Dec 31, 2024 | 15.77 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Sep 30, 2024 | -199,500.00 |
| Sep 30, 2024 | -199,500.00 |
| Mar 31, 2024 | 5.36 Mn |
| Mar 31, 2024 | 5.36 Mn |
| Dec 31, 2023 | 31.00 |
| Dec 31, 2023 | 31.00 |
| Sep 30, 2023 | 3.95 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Jun 30, 2023 | -8,147.00 |
| Jun 30, 2023 | -8,147.00 |
| Mar 31, 2023 | 5.77 Mn |
| Mar 31, 2023 | 5.77 Mn |